A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2021
This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult patients with active eosinophilic duodenitis. Subjects who complete the randomized, double-blind, placebo-controlled treatment may have the option to receive 6 doses of open-label lirentelimab (AK002) through the OLE Period of the study.
Epistemonikos ID: 99e44e1e600f27cc5b9052badcfb00abf32d78bc
First added on: Jan 28, 2022